Aduro Biotech Announces American Society of Clinical Oncology Presentation Of Promising Results From Phase 1b Clinical Trial Of Its Novel Immunotherapy For The Treatment Of Mesothelioma
6/2/2014 10:46:52 AM
CHICAGO & BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). Of the 16 evaluable patients, 69% (11/16) had confirmed durable partial responses (PR) with 25% (4/16) experiencing stable disease (SD) after CRS-207 and chemotherapy. The results were presented by Raffit Hassan, M.D., co-chief of the Thoracic and GI Oncology Branch at the National Cancer Institute, in a poster presentation at the 2014 American Society of Clinical Oncology Meeting (ASCO) held in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by